PT830604E - APOPTINA USES - Google Patents

APOPTINA USES

Info

Publication number
PT830604E
PT830604E PT96916378T PT96916378T PT830604E PT 830604 E PT830604 E PT 830604E PT 96916378 T PT96916378 T PT 96916378T PT 96916378 T PT96916378 T PT 96916378T PT 830604 E PT830604 E PT 830604E
Authority
PT
Portugal
Prior art keywords
apoptin
apoptosis
normal cells
tumor
cells
Prior art date
Application number
PT96916378T
Other languages
Portuguese (pt)
Inventor
Matheus Hubertus Mari Noteborn
Original Assignee
Leadd Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/484,939 external-priority patent/US6319693B1/en
Application filed by Leadd Bv filed Critical Leadd Bv
Publication of PT830604E publication Critical patent/PT830604E/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

This invention describes that apoptin fails to induce apoptosis in human normal cells. Besides, the invention describes that when normal cells are transformed, they become susceptible to the apoptin-induced apoptosis. The invention describes that apoptin induces in various human tumor cells a p53-distinct type of apoptosis, and cannot be blocked by a variety of apoptosis-inhibiting agents. The invention comprises an anti-tumor agent, which specifically kill tumor and not normal cells. It further provides the induction of cell death by means of gene therapy. Apoptin can induce apoptosis in non-human animal tumor cells. The invention also provides that in normal cells apoptin was found predominantly in the cytoplasm, while in tumor cells it was located in the nucleus. Besides, the invention comprises a diagnostic test for the determination of cell-transforming activity.
PT96916378T 1995-06-07 1996-06-07 APOPTINA USES PT830604E (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/484,939 US6319693B1 (en) 1990-09-12 1995-06-07 Cloning of chicken anemia virus DNA

Publications (1)

Publication Number Publication Date
PT830604E true PT830604E (en) 2003-10-31

Family

ID=23926260

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96916378T PT830604E (en) 1995-06-07 1996-06-07 APOPTINA USES

Country Status (11)

Country Link
EP (1) EP0830604B1 (en)
JP (1) JPH11506340A (en)
AT (1) ATE241808T1 (en)
AU (1) AU718422B2 (en)
CA (1) CA2221495C (en)
DE (1) DE69628431T2 (en)
DK (1) DK0830604T3 (en)
ES (1) ES2200065T3 (en)
NZ (1) NZ309171A (en)
PT (1) PT830604E (en)
WO (1) WO1996041191A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1188832A1 (en) * 2000-09-08 2002-03-20 Leadd B.V. A delivery method for the tumor specific apoptosis inducing activity of apoptin
CA2301401C (en) * 1997-08-12 2008-10-21 Leadd B.V. Determining the transforming capability of agents
DK1143994T3 (en) * 1999-01-11 2003-10-20 Leadd Bv Use of apoptosis-inducing agents in the manufacture of a medicament for the treatment of (auto) immune disorders
AU2004233486B2 (en) * 1999-01-11 2007-09-13 Leadd B.V. Use of apoptosis inducing agents in the treatment of (auto)immune diseases
PL204275B1 (en) 1999-09-02 2009-12-31 Leadd Bv Apoptin−associating protein
CA2393859A1 (en) * 1999-12-10 2001-06-14 Leadd B.V. Apoptin-associating protein
EP1186665A1 (en) * 2000-09-08 2002-03-13 Leadd B.V. A delivery method for the tumor specific apoptosis inducing activity of apoptin
AU2001294393A1 (en) * 2000-09-08 2002-03-22 Leadd B.V. A delivery method for the tumor specific apoptosis inducing activity of apoptin
EP1199363A1 (en) * 2000-10-20 2002-04-24 Leadd B.V. Phosphorylation modifications of apoptin
PT1377667E (en) * 2001-03-30 2009-03-13 Leadd Bv Fusion proteins for specific treatment of cancer and auto-immune diseases
AU2002259005A1 (en) * 2001-04-24 2002-11-05 Washington University Compositions and methods for inducing cancer cell death
WO2003089467A1 (en) * 2002-04-19 2003-10-30 Leadd B.V. Fragments of apoptin
AU2003228132A1 (en) * 2002-04-19 2003-11-03 Leadd B.V. Aberrant-specific pathways
US9403880B2 (en) 2010-11-26 2016-08-02 Institut Pasteur Identification of a human gyrovirus and applications

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981502A (en) * 1990-09-12 1999-11-09 Leadd B.V. Methods and compositions for inducing apoptosis in tumor cells
NL9301272A (en) * 1993-07-20 1995-02-16 Aesculaap Bv Chicken Anemia Virus mutants and vaccines and uses based on the viral proteins VP1, VP2 and VP3 or coding sequences of that virus.

Also Published As

Publication number Publication date
DE69628431D1 (en) 2003-07-03
DK0830604T3 (en) 2003-09-29
WO1996041191A1 (en) 1996-12-19
EP0830604A1 (en) 1998-03-25
AU718422B2 (en) 2000-04-13
ATE241808T1 (en) 2003-06-15
CA2221495A1 (en) 1996-12-19
ES2200065T3 (en) 2004-03-01
DE69628431T2 (en) 2004-05-06
CA2221495C (en) 2010-06-01
JPH11506340A (en) 1999-06-08
EP0830604B1 (en) 2003-05-28
AU5913696A (en) 1996-12-30
NZ309171A (en) 2000-04-28

Similar Documents

Publication Publication Date Title
Green et al. Cutaneous squamous cell carcinoma: an epidemiological review
PT830604E (en) APOPTINA USES
Naito et al. TRAF6-deficient mice display hypohidrotic ectodermal dysplasia
Kelly et al. Projections from the superior olive and lateral lemniscus to tonotopic regions of the rat's inferior colliculus
Smith et al. The two faces of tumor suppressor p53.
DE69231245D1 (en) CHANGED GENES IN HUMAN COLOREECTAL CANCER
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
Whiteman et al. Melanoma and sun exposure: where are we now?
GB2465940A (en) Neural tumor stem cells and methods of use thereof
DE69233399D1 (en) HUMAN CYCLIN E
CY1109868T1 (en) CD81 PROFESSIONAL SUBSCRIPTION PROTECTOR C
Fukai et al. Enhanced anti-tumor effect of zoledronic acid combined with temozolomide against human malignant glioma cell expressing O6-methylguanine DNA methyltransferase
MX9706107A (en) Methods and uses for apoptin.
ATE350662T1 (en) MARKER PROTEINS FOR PROSTATE CANCER
Fadadu et al. Ultraviolet A radiation exposure and melanoma: A review
WO2000018961A3 (en) Expression analysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
DK1185279T3 (en) Agents for the treatment of malignant diseases using the protein YB-1
WO2003098223A3 (en) A method for killing cells by inhibiting histone activity in the cell
ES2174103T3 (en) USE OF WAP OR MMTV REGULATORY SEQUENCES FOR DIRECT EXPRESSION OF HETEROLOGICAL GENES LINKED IN HUMAN MAMMARY CELLS, INCLUDING HUMAN MAMMARY CARCINOMA CELLS.
Guthrie Dynamic compartmentalization of DNA repair proteins within spiral ganglion neurons in response to noise stress
MX9709860A (en) Methods and uses for apoptin.
Liao et al. Hypofractionation: what does it mean for prostate cancer treatment?
Frankenberg-Schwager et al. Chromosomal instability induced by mammography X-rays in primary human fibroblasts from BRCA1 and BRCA2 mutation carriers
TR199902866T2 (en) New BPC peptide salts with organoprotective activity, processes for their preparation and use in therapy.
BR0207327A (en) Biotin-derived amino acids and their conjugates with macrocyclic chelating agents